论文信息 - An evaluation of the FDA Responder Endpoint for IBS‐C clinical trials: analysis of data from linaclotide Phase 3 clinical trials - 字舞流文

An evaluation of the FDA Responder Endpoint for IBS‐C clinical trials: analysis of data from linaclotide Phase 3 clinical trials

L. Nelson | M. Currie | S. Shiff | A. Lembo | M. Baird | R. Carson | J. Johnston | C. Kurtz | J. Macdougall | B. Lavins | K. Shi | J. E. MacDougall | B. J. Lavins | V. Williams | S. J. Shiff